FY2017 · ended Dec 31, 2017 · Revenue $191,077, -22.5% YoY · Filed Apr 2, 2018
Bioxytran, Inc. (BIXT) files with the SEC under industry code 2834, Pharmaceutical Preparations.
Revenue (TTM)
$177,794
-13.8% vs year-ago TTM
Net income (TTM)
$5,906
+101.5% vs year-ago TTM
Operating cash flow (TTM)
$-874,319
-97.8% vs year-ago TTM
Free cash flow
—
EPS
$-0.02
+0.0% vs prior year
Dividend per share
None
Shares outstanding
113.36M
+27.5% vs prior year
Net cash
$-42,846
FY 2024
Operating margin
5.5%
FY 2018
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- BIXT (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- NV
- Headquarters
- Needham, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1445815
- Former names
- U.S. RARE EARTH MINERALS, INC. (until Oct 30, 2018); U.S. RARE EARTH MINERALS, INC (until Oct 3, 2018); U.S. Natural Nutrients & Minerals, Inc. (until Apr 14, 2011); AMERICA'S DRIVING RANGES, INC. (until Oct 29, 2009)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$1.8M | -$2.2M | -$3.8M | -$2.4M | -$4.2M |
| Net income | -$2.1M | -$2.4M | -$4.5M | -$2.5M | -$4.0M |
| Diluted EPS | -$0.02 | -$0.02 | -$0.03 | — | — |
| Operating cash flow | -$526,455 | -$381,316 | -$775,375 | -$1.8M | -$1.7M |
| Total assets | $658,552 | $138,694 | $139,382 | $370,936 | $119,290 |
| Total liabilities | $3.2M | $1.9M | $3.2M | $3.7M | $3.3M |
| Stockholders' equity | -$2.6M | -$1.8M | -$3.1M | -$3.3M | — |
| Cash and investments | $509,914 | $5,154 | $26,086 | $295,401 | $72,358 |
| Total debt | — | $48,000 | — | — | — |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Other events
|
Aug 11, 2026 | Aug 11, 2026 |
| 10-Q | Quarterly report | May 15, 2026 | Mar 31, 2026 |
| 10-K | Annual report | Apr 15, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Unregistered share sale, Other events
|
Mar 20, 2026 | Mar 20, 2026 |
| 8-K |
Current report
Change to shareholder rights, Officer or director change, Bylaw or fiscal year change
|
Mar 13, 2026 | Mar 12, 2026 |
All 469 Bioxytran, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.